Posterior Reversible Encephalopathy Syndrome (PRES) Following Fruquintinib in a Normotensive Patient With Metastatic Colorectal Cancer: A Case Report.

Rawan ElManfalouty, Ahmed Holayel, Ian Russell, Kalena Marti

Abstract readCase Reports

In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Posterior reversible encephalopathy syndrome across 22 VEGF-pathway inhibitors in the FDA adverse event reporting system: reporting patterns and reporting-interval characteristics.Frontiers in pharmacology · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rawan ElManfaloutyOncology, The Christie NHS Foundation Trust, Manchester, GBR.

Ahmed HolayelOncology, Maidstone and Tunbridge Wells NHS Trust, Kent, GBR.

Ian RussellRadiology, The Christie NHS Foundation Trust, Manchester, GBR.

Kalena MartiOncology, The Christie NHS Foundation Trust, Manchester, GBR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a rare case of posterior reversible encephalopathy syndrome (PRES) following fruquintinib treatment in a 71-year-old female with metastatic colorectal adenocarcinoma harbouring a KRAS G12D mutation. The patient had previously undergone multiple lines of chemotherapy and surgical resections with stable disease before receiving fruquintinib under compassionate access. After two cycles, she developed headaches and acute encephalopathy. MRI confirmed PRES without associated hypertension. Fruquintinib was discontinued, and the patient made a full neurological recovery. This case highlights a rare but significant toxicity of anti-vascular endothelial growth factor (VEGF) therapy in the colorectal cancer setting and underscores the importance of early radiological evaluation in suspected PRES.

Indexed as

chemotherapy-related toxicitymetastatic colorectal cancer (mcrc)neurotoxicposterior reversible encephalopathy syndrome (pres)vegfr inhibitor

Identifiers

PMID41450417

DOI10.7759/cureus.97598

PMCPMC12728244

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.